98%
921
2 minutes
20
Merkel cell carcinoma is a rare, aggressive skin tumor initiated by polyomavirus integration or UV light DNA damage. In New Zealand, there is a propensity toward the UV-driven form (31 of 107, 29% virus positive). Using archival formalin-fixed, paraffin-embedded tissues, we report targeted DNA sequencing covering 246 cancer genes on 71 tumor tissues and 38 nonmalignant tissues from 37 individuals, with 33 of 37 being negative for the virus. Somatic variants of New Zealand virus-negative Merkel cell carcinomas partially overlapped with those reported overseas, including TP53 variants in all tumors and RB1, LRP1B, NOTCH1, and EPHA3/7 variants each found in over half of the cohort. Variants in genes not analyzed or reported in previous studies were also found. Cataloging variants in TP53 and RB1 from published datasets revealed a broad distribution across these genes. Chr 1p gain and Chr 3p loss were identified in around 50% of New Zealand virus-negative Merkel cell carcinomas, and RB1 loss of heterozygosity was found in 90% of cases. Copy number variants accumulate in most metastases. Virus-negative Merkel cell carcinomas have complex combinations of somatic DNA-sequence variants and copy number variants. They likely carry the small genomic changes permissive for metastasis from early tumor development; however, chromosomal alterations may contribute to driving metastatic progression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jid.2023.01.015 | DOI Listing |
Biomed Pharmacother
September 2025
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address:
Various viruses are widely recognized as key contributors to the development of numerous hematological malignancies and solid tumors. It is estimated that virus-associated cancers account for approximately 1.5 million new cases globally each year.
View Article and Find Full Text PDFDermatol Surg
September 2025
Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
J Cutan Pathol
August 2025
Dermatopathology, KorPath, Tampa, Florida, USA.
Cutaneous large cell neuroendocrine carcinoma (LCNEC) is a rare and poorly understood malignancy. Here we describe the clinicopathological characteristics of six cutaneous LCNEC case. A retrospective chart and slide review of PCLCNEC cases at a large commercial dermatopathology practice from January 2017 to May 2025 was performed.
View Article and Find Full Text PDFMethods Mol Biol
August 2025
Ludwig-Maximilians-University, Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Munich, Germany.
Messenger RNA (mRNA)-based CRISPR-Cas9 delivery is considered an advanced gene-editing strategy due to its rapid onset, transient expression, and reduced off-target effects, building on the success of mRNA therapeutics. However, challenges remain, particularly in efficiently co-delivering both Cas9 mRNA and single guide RNA (sgRNA). Here, we describe a straightforward fluorescence-labeling method for tracking the co-localization and stability of Cas9 mRNA and sgRNA in cells using confocal microscopy.
View Article and Find Full Text PDFMethods Mol Biol
August 2025
Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University Munich, Munich, Germany.
The approval of ONPATTRO® in 2018 resembled a milestone for small interfering RNA (siRNA) therapies, introducing the first siRNA lipid nanoparticle (LNP) into clinical use. This breakthrough has improved research efforts in siRNA-based therapeutics. Similarly, benefits like scalability and adaptability have led to enormous research also in polymeric siRNA delivery systems, leading to polyplexes or micelleplexes after complexation.
View Article and Find Full Text PDF